Evidence map›Paper›PMID 24066662›Full record

ArticleHuman gene therapy methods2014

An independent construct for conditional expression of atonal homolog-1.

Mark A Parker, Yen-fu Cheng, Hikaru Kinouchi, Rebecca Bieber, Albert S B Edge

Abstract read
In one paragraph

Article in Human gene therapy methods, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Emerging Gene Therapies for Genetic Hearing Loss.Journal of the Association for Research in Otolaryngology : JARO · 2017
    Review
  2. In Vivo Interplay between p27Cell reports · 2017
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mark A Parker1 Department of Otolaryngology Head & Neck Surgery, Tufts University School of Medicine , Boston, MA 02111.
Yen-fu Cheng
Hikaru Kinouchi
Rebecca Bieber
Albert S B Edge
Tufts University · USMassachusetts Eye and Ear Infirmary · US

Funding

Imaging Core PlanP30DC005209 · NIDCD · MASSACHUSETTS EYE AND EAR INFIRMARY · PI LIBERMAN, M. CHARLES · 2002 to 2016
$12.0M
Cellular therapy for the inner earR01DC007174 · NIDCD · MASSACHUSETTS EYE AND EAR INFIRMARY · PI EDGE, ALBERT · 2005 to 2017
$4.6M
Targeted Expression of Atoh1 in Cochlear Supporting CellsR03DC010065 · NIDCD · GENESYS RESEARCH INSTITUTE, INC. · PI PARKER, MARK A · 2009 to 2011
$484k
NIDCD NIH HHS P30DC05209NIDCD NIH HHS R01DC007174NIDCD NIH HHS R03DC010065
6 · The paper itself

Abstract

The mammalian homolog of the basic helix-loop-helix transcription factor atonal-1 (Atoh1 or Math1) is required for development of cochlear hair cells that function as the mechanosensory cells required for audition. Forced expression of Atoh1 in cochlear-supporting cells may provide a way to regenerate hair cells and provide for a therapy for hearing loss. Additionally, Atoh1 is an inhibitor of proliferation and has further clinical applications in anticancer therapies. The goal of these experiments was to improve the method for Atoh1 expression by engineering a genetic construct that may be used in future translational applications. To address the poor control of Atoh1 expression in standard gene expression systems where Atoh1 is expressed constitutively at abnormally elevated levels, our aim was to engineer an inducible system whereby Atoh1 was upregulated by an inducer and downregulated once the inducer was removed. A further aim was to engineer a single genetic construct that allowed for conditional expression of Atoh1 independent of secondary regulatory elements. Here we describe a stand-alone genetic construct that utilizes the tamoxifen sensitivity of a mutated estrogen receptor (ER) ligand-binding domain for the conditional expression of Atoh1. The Atoh1-ER-DsRed construct is translated into an ATOH1-ER-DSRED fusion protein that remains sequestered in the cytoplasm and therefore rendered inactive because it cannot enter the nucleus to activate Atoh1 signaling pathways. However, application of 4-hydroxytamoxifen results in translocation of the fusion protein to the nucleus, where it binds to the Atoh1 enhancer, upregulates transcription and translation of endogenous ATOH1 and activates downstream Atoh1 signaling such as upregulation of the hair cell protein MYOSIN 7A. Removal of tamoxifen reverses the upregulation of endogenous Atoh1 signaling. This construct serves as an independent genetic construct that allows for the conditional upregulation and downregulation of Atoh1, and may prove useful for manipulating Atoh1 expression in vivo.

Indexed as

AnimalsBasic Helix-Loop-Helix ProteinsCells, CulturedGenetic VectorsHumansMiceMyosinsOrgan of CortiPromoter Regions, GeneticProtein BindingReceptors, EstrogenRecombinant Fusion ProteinsRNA, MessengerSignal TransductionTamoxifenTransfectionafimoxifeneATOH1 protein, humanBasic Helix-Loop-Helix ProteinsMyosinsReceptors, EstrogenRecombinant Fusion ProteinsRNA, MessengerTamoxifen

Identifiers

PMID24066662
PMCPMC3904653
OpenAlexW2065519221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.